Adaptive Biotechnologies (ADPT) & Its Peers Head-To-Head Review

Adaptive Biotechnologies (NASDAQ:ADPT) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Adaptive Biotechnologies to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Adaptive Biotechnologies and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1	1	6	0	2.62
Adaptive Biotechnologies Competitors	948	3168	5486	178	2.50

Adaptive Biotechnologies presently has a consensus price target of $30.06, suggesting a potential upside of 12.55%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.82%. Given Adaptive Biotechnologies’ stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than its rivals.

Profitability

This table compares Adaptive Biotechnologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Adaptive Biotechnologies Competitors	-540.60%	-166.50%	-13.58%

Risk & Volatility

Adaptive Biotechnologies has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies’ rivals have a beta of 0.94, meaning that their average stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Adaptive Biotechnologies and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08 million	-$59.50 million	-65.15
Adaptive Biotechnologies Competitors	$2.28 billion	$55.88 billion	-14.01

Adaptive Biotechnologies’ rivals have higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Adaptive Biotechnologies beats its rivals on 7 of the 13 factors compared.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.